236 related articles for article (PubMed ID: 21946352)
1. Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.
Prickett TD; Wei X; Cardenas-Navia I; Teer JK; Lin JC; Walia V; Gartner J; Jiang J; Cherukuri PF; Molinolo A; Davies MA; Gershenwald JE; Stemke-Hale K; Rosenberg SA; Margulies EH; Samuels Y
Nat Genet; 2011 Sep; 43(11):1119-26. PubMed ID: 21946352
[TBL] [Abstract][Full Text] [Related]
2. ERBB4 mutation analysis: emerging molecular target for melanoma treatment.
Lau C; Killian KJ; Samuels Y; Rudloff U
Methods Mol Biol; 2014; 1102():461-80. PubMed ID: 24258993
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated GRM3 variants dysregulate melanosome trafficking and cAMP signaling.
Neto A; Ceol CJ
Pigment Cell Melanoma Res; 2018 Jan; 31(1):115-119. PubMed ID: 28646617
[TBL] [Abstract][Full Text] [Related]
4. Circ_0079593 facilitates proliferation, metastasis, glucose metabolism and inhibits apoptosis in melanoma by regulating the miR-516b/GRM3 axis.
Lu J; Li Y
Mol Cell Biochem; 2020 Dec; 475(1-2):227-237. PubMed ID: 32839935
[TBL] [Abstract][Full Text] [Related]
5. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
6. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
7. Exome sequencing identifies GRIN2A as frequently mutated in melanoma.
Wei X; Walia V; Lin JC; Teer JK; Prickett TD; Gartner J; Davis S; ; Stemke-Hale K; Davies MA; Gershenwald JE; Robinson W; Robinson S; Rosenberg SA; Samuels Y
Nat Genet; 2011 May; 43(5):442-6. PubMed ID: 21499247
[TBL] [Abstract][Full Text] [Related]
8. Quantitative expression profiling of G-protein-coupled receptors (GPCRs) in metastatic melanoma: the constitutively active orphan GPCR GPR18 as novel drug target.
Qin Y; Verdegaal EM; Siderius M; Bebelman JP; Smit MJ; Leurs R; Willemze R; Tensen CP; Osanto S
Pigment Cell Melanoma Res; 2011 Feb; 24(1):207-18. PubMed ID: 20880198
[TBL] [Abstract][Full Text] [Related]
9. G-protein-coupled receptors and melanoma.
Lee HJ; Wall B; Chen S
Pigment Cell Melanoma Res; 2008 Aug; 21(4):415-28. PubMed ID: 18582227
[TBL] [Abstract][Full Text] [Related]
10. Glutamate receptors: emerging players in melanomagenesis.
Wangari-Talbot J; Chen S
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1082-3. PubMed ID: 22216442
[No Abstract] [Full Text] [Related]
11. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
12. KIT mutations in ocular melanoma: frequency and anatomic distribution.
Wallander ML; Layfield LJ; Emerson LL; Mamalis N; Davis D; Tripp SR; Holden JA
Mod Pathol; 2011 Aug; 24(8):1031-5. PubMed ID: 21478825
[TBL] [Abstract][Full Text] [Related]
13. Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations.
Demunter A; Libbrecht L; Degreef H; De Wolf-Peeters C; van den Oord JJ
Mod Pathol; 2002 Apr; 15(4):454-61. PubMed ID: 11950921
[TBL] [Abstract][Full Text] [Related]
14. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma.
Wei X; Prickett TD; Viloria CG; Molinolo A; Lin JC; Cardenas-Navia I; Cruz P; ; Rosenberg SA; Davies MA; Gershenwald JE; López-Otín C; Samuels Y
Mol Cancer Res; 2010 Nov; 8(11):1513-25. PubMed ID: 21047771
[TBL] [Abstract][Full Text] [Related]
15. GNAQ and GNA11 mutations in uveal melanoma.
Shoushtari AN; Carvajal RD
Melanoma Res; 2014 Dec; 24(6):525-34. PubMed ID: 25304237
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
17. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Walia V; Prickett TD; Kim JS; Gartner JJ; Lin JC; Zhou M; Rosenberg SA; Elble RC; Solomon DA; Waldman T; Samuels Y
Hum Mutat; 2014 Nov; 35(11):1301-10. PubMed ID: 25113440
[TBL] [Abstract][Full Text] [Related]
18. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
19. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
20. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
